Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.

Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

0

EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022

EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022

0

EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022

EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

0

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22

0

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.: https://mms.businesswire.com/media/20221208005302/en/1658991/5/Dinner.jpg

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous

BusinessWire_EN

0

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.: https://mms.businesswire.com/media/20221208005302/en/1658991/5/Dinner.jpg

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous

BusinessWire_EN

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program

EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program

0

EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program

EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png

EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth

EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth

0

EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png

EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

0

EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png

EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care

EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care

0

EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png

EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board

EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

0

Form 8.3 - The Vanguard Group, Inc.: Sanofi: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23760/234px-Sanofi_2011_logo.svg.png

Form 8.3 - The Vanguard Group, Inc.: Sanofi

Form 8.3 - The Vanguard Group, Inc.: Sanofi

0

Form 8.3 - The Vanguard Group, Inc.: Sanofi: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23760/234px-Sanofi_2011_logo.svg.png

Form 8.3 - The Vanguard Group, Inc.: Sanofi

Form 8.3 - The Vanguard Group, Inc.: Sanofi

0

Form 8.3 - The Vanguard Group, Inc.: Sanofi: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23760/234px-Sanofi_2011_logo.svg.png

Form 8.3 - The Vanguard Group, Inc.: Sanofi

Form 8.3 - The Vanguard Group, Inc.: Sanofi

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Amgen Inchttp://commons.wikimedia.org/wiki/File:Amgen.svg: AMGEN INC.

Form 8.3 - The Vanguard Group, Inc.: Amgen Inc

Form 8.3 - The Vanguard Group, Inc.: Amgen Inc

0